<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32515889</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2328-9503</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Annals of clinical and translational neurology</Title><ISOAbbreviation>Ann Clin Transl Neurol</ISOAbbreviation></Journal><ArticleTitle>Improved ALS clinical trials through frequent at-home self-assessment: a proof of concept study.</ArticleTitle><Pagination><StartPage>1148</StartPage><EndPage>1157</EndPage><MedlinePgn>1148-1157</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/acn3.51096</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To determine the potential for improving amyotrophic lateral sclerosis (ALS) clinical trials by having patients or caregivers perform frequent self-assessments at home.</AbstractText><AbstractText Label="METHODS AND PARTICIPANTS">We enrolled ALS patients into a nonblinded, longitudinal 9-month study in which patients and caregivers obtained daily data using several different instruments, including a slow-vital capacity device, a hand grip dynamometer, an electrical impedance myography-based fitness device, an activity tracker, a speech app, and the ALS functional rating scale-revised. Questions as to acceptability were asked at two time points.</AbstractText><AbstractText Label="RESULTS">A total of 113 individuals enrolled, with 61 (43 men, 18 women, mean age 60.1&#xa0;&#xb1;&#xa0;9.9&#xa0;years) collecting a minimum of 7&#xa0;days data and being included in the analysis. Daily measurements resulted in more accurate assessments of the slope of progression of the disease, resulting in smaller sample size estimates for a hypothetical clinical trial. For example, by performing daily slow-vital capacity measurements, calculated sample size was reduced to 182 subjects/study arm from 882/arm for monthly measurements. Similarly, performing the ALS functional rating scale weekly rather than monthly led to a calculated sample size of 73/arm as compared to 274/arm. Participants generally found the procedures acceptable and, for many, improved their sense of control of their disease.</AbstractText><AbstractText Label="INTERPRETATION">Frequent at-home measurements using standard tools holds the prospect of tracking progression and reducing sample size requirements for clinical trials in ALS while also being acceptable to the patients. Future studies in this and other neurological disorders should consider adopting this approach to data collection.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rutkove</LastName><ForeName>Seward B</ForeName><Initials>SB</Initials><Identifier Source="ORCID">0000-0002-6375-3312</Identifier><AffiliationInfo><Affiliation>Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Narayanaswami</LastName><ForeName>Pushpa</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berisha</LastName><ForeName>Visar</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Arizona State University, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liss</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Arizona State University, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hahn</LastName><ForeName>Shira</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Arizona State University, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shelton</LastName><ForeName>Kerisa</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Barrow Neurological Clinic, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qi</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pandeya</LastName><ForeName>Sarbesh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shefner</LastName><ForeName>Jeremy M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Barrow Neurological Clinic, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Clin Transl Neurol</MedlineTA><NlmUniqueID>101623278</NlmUniqueID><ISSNLinking>2328-9503</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Ann Clin Transl Neurol. 2020 Oct;7(10):2074-2075</RefSource><PMID Version="1">32946644</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Ann Clin Transl Neurol. 2020 Oct;7(10):2076-2077</RefSource><PMID Version="1">32946678</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Ann Clin Transl Neurol. 2021 Aug;8(8):1770</RefSource><PMID Version="1">34369672</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059026" MajorTopicYN="N">Diagnostic Self Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018737" MajorTopicYN="N">Hand Strength</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009213" MajorTopicYN="N">Myography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017064" MajorTopicYN="N">Process Assessment, Health Care</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000075082" MajorTopicYN="N">Proof of Concept Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018401" MajorTopicYN="N">Sample Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014797" MajorTopicYN="N">Vital Capacity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Dr. Rutkove holds equity in Myolex, Inc, (the company that produces the Skulpt<sup>&#xae;</sup> Scanner), has served on the board of directors, has received consulting income from the company, and is named as an inventor on patents owned or licensed to Myolex, Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32515889</ArticleId><ArticleId IdType="pmc">PMC7359124</ArticleId><ArticleId IdType="doi">10.1002/acn3.51096</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994;330:585&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, van den Berg LH, Shefner JM, et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double&#x2010;blind, phase 3 trial. Lancet Neurol 2013;12:1059&#x2013;1067.</Citation><ArticleIdList><ArticleId IdType="pubmed">24067398</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Aoki M, Tsuji S, et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double&#x2010;blind, placebo&#x2010;controlled trial. Lancet Neurol 2017;16:505&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, Cudkowicz ME, Hardiman O, et al. A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2019;20:584&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pubmed">31081694</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutkove SB, Qi K, Shelton K, et al. ALS longitudinal studies with frequent data collection at home: study design and baseline data. Amyotroph Lateral Scler Frontotemporal Degener 2019;20:61&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6513689</ArticleId><ArticleId IdType="pubmed">30486680</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, Rutkove SB, Caress JB, et al. Assessing ALS progression with a dedicated electrical impedance myography system. Amyotroph Lateral Scler Frontotemporal Degener 2018; 19(7&#x2010;8): 555&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6438779</ArticleId><ArticleId IdType="pubmed">30265154</ArticleId></ArticleIdList></Reference><Reference><Citation>Peplinski J, Berisha V, Liss J, et al. Objective assessment of vocal tremor. Proceedings of the &#x2026; IEEE International Conference on Acoustics, Speech, and Signal Processing. ICASSP (Conference) 2019;2019:6386&#x2013;6390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6939668</ArticleId><ArticleId IdType="pubmed">31896954</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS&#x2010;R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 1999;169:13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan TP. Sample size determination and power. Hoboken, NJ, USA: John Wiley &amp; Sons; 2013.</Citation></Reference><Reference><Citation>Bedlack RS, Wicks P, Vaughan T, et al. Lunasin does not slow ALS progression: results of an open&#x2010;label, single&#x2010;center, hybrid&#x2010;virtual 12&#x2010;month trial. Amyotroph Lateral Scler Frontotemporal Degener 2019;20:285&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">30663902</ArticleId></ArticleIdList></Reference><Reference><Citation>Orri M, Lipset CH, Jacobs BP, et al. Web&#x2010;based trial to evaluate the efficacy and safety of tolterodine ER 4 mg in participants with overactive bladder: REMOTE trial. Contemp Clin Trials 2014;38:190&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">24792229</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>